Literature DB >> 9498962

Predictors of short- and long-term survival in HIV-infected patients admitted to the ICU.

E Casalino1, G Mendoza-Sassi, M Wolff, J P Bédos, C Gaudebout, B Regnier, F Vachon.   

Abstract

STUDY
OBJECTIVES: To evaluate the prognosis of HIV-infected patients admitted to ICUs and to identify factors predictive of short- and long-term survival.
DESIGN: A prospective study from January 1, 1990, to December 31, 1992, including all consecutive HIV-infected patients admitted to our ICU for the first time. ICU survivors were followed up until January 1, 1994.
SETTING: An 18-bed infectious diseases ICU in a 1,300-bed university hospital in Paris. PATIENTS: Four hundred twenty-one HIV-related admissions were recorded during the study period (33.5% of 1,258 admissions to ICU); 354 HIV-infected patients were first ICU admissions and were analyzed. MEASUREMENTS AND
RESULTS: Predictive factors on univariate and multivariate analyses (logistic regression and Cox model) for short- and long-term mortality were performed. Respiratory failure was the main cause of admission (49.2%), followed by neurologic disorders (26.8%), sepsis (10.2%), heart failure (4.5%), and miscellaneous disorders (9.3%). For these groups, in-ICU and in-hospital mortality rates were as follows: 16.7% and 33.9%; 23.2% and 41.1%; 38.9% and 58.3%; 25% and 68.8%; and 12.1% and 24.2%, respectively. In-ICU and in-hospital mortality rates were significantly different across the groups (p=0.026 and 0.002, respectively). Multivariate analysis showed that the in-hospital outcome was significantly associated with functional status (p=0.05), time since AIDS diagnosis (p=0.04), HIV disease stage (0.016), simplified acute physiology score (SAPS I) (p=0.06), need for mechanical ventilation (p<0.000001), and its duration (p=0.0001). In the 281 patients who were discharged alive from the ICU, cumulative survival rates were 51%+/-38% at 6 months, 28%+/-38% at 12 months, and 18%+/-30% at 24 months. Median and crude mean+/-SD survival times were 199 days and 316+/-343 days. Multivariate analysis showed that the long-term outcome was significantly associated with functional status (p=0.000001), weight loss (p=0.00001), the CD4 count (p=0.00001), the HIV disease stage (p=0.01), the duration of AIDS (p=0.001), the admission cause group (p=0.03), and the SAPS I at admission (p=0.00001).
CONCLUSIONS: The short-term (in-ICU and in-hospital) outcome of HIV-infected patients was mainly related to the severity of the acute illness (SAPS I, cause of admission, need for and duration of mechanical ventilation), and to the preadmission health status, based on functional status and weight loss. Some of these parameters, in particular the SAPS I and preadmission health status, also influenced the long-term outcome. Whereas HIV-related variables had little impact on the in-ICU outcome, they were closely related with the in-hospital outcome and even more strikingly with the long-term outcome. Thus, the life expectancy of HIV-infected patients, which depends primarily on the natural history of the HIV infection, is the most powerful determinant of the long-term prognosis. Our results confirm that ICU support for HIV-infected patients should not be considered futile.

Entities:  

Mesh:

Year:  1998        PMID: 9498962     DOI: 10.1378/chest.113.2.421

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  16 in total

Review 1.  The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia.

Authors:  R J Boyton; D M Mitchell; O M Kon
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

2.  [Treatment of neuro-AIDS on a neurological intensive care unit: epidemiology and predictors of outcome].

Authors:  O Braicks; K Anneken; D Reichelt; W R Schäbitz; R Dziewas; S Evers; I W Husstedt
Journal:  Nervenarzt       Date:  2011-10       Impact factor: 1.214

3.  Successful treatment of HIV-associated multicentric Castleman's disease and multiple organ failure with rituximab and supportive care: a case report.

Authors:  Robin H Johns; Tomas Doyle; Marc C Lipman; Kate Cwynarski; Joanne R Cleverley; Peter G Isaacson; Steve Shaw; Banwari Agarwal
Journal:  J Med Case Rep       Date:  2010-01-30

Review 4.  Critical illness in HIV-infected patients in the era of combination antiretroviral therapy.

Authors:  Kathleen M Akgün; Laurence Huang; Alison Morris; Amy C Justice; Margaret Pisani; Kristina Crothers
Journal:  Proc Am Thorac Soc       Date:  2011-06

5.  Characteristics and outcomes of HIV-infected patients in the ICU: impact of the highly active antiretroviral treatment era.

Authors:  Benoît Vincent; Jean-François Timsit; Marc Auburtin; Frédérique Schortgen; Lila Bouadma; Michel Wolff; Bernard Regnier
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

6.  Benefit of antiretroviral therapy on survival of human immunodeficiency virus-infected patients admitted to an intensive care unit.

Authors:  Julio Croda; Mariana Garcia Croda; Alan Neves; Sigrid De Sousa dos Santos
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

7.  Should highly active antiretroviral therapy be prescribed in critically ill HIV-infected patients during the ICU stay? A retrospective cohort study.

Authors:  Agnes Meybeck; Lydie Lecomte; Michel Valette; Nicolas Van Grunderbeeck; Nicolas Boussekey; Arnaud Chiche; Hugues Georges; Yazdan Yazdanpanah; Olivier Leroy
Journal:  AIDS Res Ther       Date:  2012-09-28       Impact factor: 2.250

8.  Intensive Care Usage by HIV-Positive Patients in the HAART Era.

Authors:  L Turtle; R Vyakernam; A Menon-Johansson; M R Nelson; N Soni
Journal:  Interdiscip Perspect Infect Dis       Date:  2011-10-30

Review 9.  Metabolic and immunologic derangements in cardiac cachexia: where to from here?

Authors:  Sabine Strassburg; Stefan D Anker
Journal:  Heart Fail Rev       Date:  2006-03       Impact factor: 4.654

10.  C-reactive protein/albumin ratio predicts 90-day mortality of septic patients.

Authors:  Otavio T Ranzani; Fernando Godinho Zampieri; Daniel Neves Forte; Luciano Cesar Pontes Azevedo; Marcelo Park
Journal:  PLoS One       Date:  2013-03-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.